Conclusion: These results indicate the potential of nutlin-3a as an alternative agent for treating KRAS mutant/p53 wild type NSCLC cells.doi:10.1186/s13046-023-02922-8Kim, DasomMin, DongwhaKim, JooheeKim, Min JungSeo, YerimJung, Byung Hwa...
Pilotto S, Molina-Vila MA, Karachaliou N, et al. Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. Tr...
In the KRAS-mutant lung cancer model, blockade of both PD-1 and helix-loop-helix transcription factor inhibitor of differentiation 1 knock out significantly enhances the amount of CD8+ T cells as well as the expression of PD-L1, which impairs the tumor growth and increases the survival[126]...
(2019). The combination of MEK Inhibitor with immunomodulatory antibodies targeting programmed death 1 and programmed death ligand 1 results in prolonged survival in Kras/p53-driven lung cancer. Journal of Thoracic Oncology, 14(6), 1046–1060. https://doi.org/10.1016/j.jtho.2019.02.004FromNLM ...
and they have Treg-disruptive effects in a non–small cell lung cancer (NSCLC) model. Targeting PD-1–inhibitory signals through PD-1 antibody blockade also has substantial therapeutic impact in lung cancer, although these...
et al. Comprehensive molecular profiling of lung adenocarcinoma: The Cancer Genome Atlas Research Network. Nature 511, 543–550 (2014). Article CAS Google Scholar Feldser, D. M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572–575 (2010)....
The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner Anna-Lena Meinhardt Enkhtsetseg Munkhbaatar Philipp J. Jost Brief CommunicationOpen Access29 Jan 2022 Oncogene A low amino acid environment promotes cell macropinocytosis through the YY1-FGD6 axis...
RAF1 kinase activity is dispensible for KRAS/p53 mutant lung tumor progression Cancer Cell, 39 (3) (2021), pp. 294-296 doi:2021/01/30 Google Scholar Sanclemente et al., 2018 M. Sanclemente, S. Francoz, L. Esteban-Burgos, E. Bousquet-Mur, M. Djurec, P.P. Lopez-Casas, M. Hida...
*使用本品系发表的文献需注明: Kras-LSL-G12D mice (Cat. NO. NM-KI-190003) were purchased from Shanghai Model Organisms Center, Inc.. 疾病预测 膀胱癌 Urinary Bladder Cancer 近似模型的表型 MGI:5790500 注:该品系与Ctnnb1-Flox(NM-CKO-200154)和Upk2-cre工具鼠交配才可能获得预期表型 ...
Mutant KRAS (KM), the most common oncogene in lung cancer (LC), regulates fatty acid (FA) metabolism. However, the role of FA in LC tumorigenesis is still not sufficiently characterized. Here, we show that KMLC has a specific lipid profile, with high triacylglycerides and phosphatidylcholine...